BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 4023831)

  • 1. [Tumor markers in breast cancer].
    Polevaia EB; Tkacheva GA; Letiagin VP; Ivanov VM; Koposova TL
    Sov Med; 1985; (3):25-9. PubMed ID: 4023831
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ferritin, CEA and TPA as tumor markers in breast neoplasms].
    Bonanni F; Folco U; Giudici Cipriani A; Buffa E; Amedeo A; Bertolotto M; Rembado R; Barbetti V; Guglieri F
    Minerva Med; 1985 Sep; 76(34-35):1533-4. PubMed ID: 4034052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advantages and limitations of combined assays of 4 serum markers in various types of malignant neoplasms].
    Lanza E; Coda C; Ramella S; Ciambellotti E; Moro G; Cartia GL
    Minerva Med; 1986 Sep; 77(34-35):1521-5. PubMed ID: 3463886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The tumor markers TPA and CEA in the after care of breast cancer].
    Beaufort F; Fueger GF; Steiner H
    Wien Med Wochenschr; 1985 Feb; 135(4):85-8. PubMed ID: 2986366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Human breast cancer markers].
    Remennik LV
    Eksp Onkol; 1985; 7(4):3-8. PubMed ID: 2994992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tissue polypeptide and carcinoembryonic antigens in patients with breast cancer].
    Polevaia EB; Tkacheva GA; Ivanov VM; Koposova TL
    Vopr Onkol; 1984; 30(3):9-13. PubMed ID: 6710954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of serum tumor markers (CEA, TPA, IAP and ferritin) in pulmonary tuberculosis].
    Komatsu H
    Kekkaku; 1987 Jan; 62(1):31-6. PubMed ID: 3573509
    [No Abstract]   [Full Text] [Related]  

  • 8. Differential immunocytochemical localization of tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) in breast cancer.
    Björklund V; Björklund B
    Cancer Detect Prev; 1983; 6(1-2):193-8. PubMed ID: 6883380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes in carcinoembryonic antigen and tissue polypeptide antigen in monitoring the post-operative course of some tumor types].
    Ciaccio B; Caponi A; Cappetti P; Fanciullacci A; Bartoli P; Berti P
    Quad Sclavo Diagn; 1985 Jun; 21(2):199-205. PubMed ID: 4080962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tissue polypeptide antigen in breast cancer].
    Nomizu T; Watanabe I; Endo S
    Nihon Gan Chiryo Gakkai Shi; 1984 Dec; 19(10):2287-95. PubMed ID: 6085339
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimizing tumor markers in breast cancer: monitoring, prognosis, and therapy control.
    Staab HJ; Ahlemann LM; Anderer FA; Zwirner M; Schindler AE
    Cancer Detect Prev; 1985; 8(1-2):35-45. PubMed ID: 4064050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical significance of tissue polypeptide antigen in breast cancer patients.
    Mross K; Bandlow G
    Anticancer Res; 1986; 6(2):223-5. PubMed ID: 3707059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Possibility of using tumor markers, pituitary gonadotropic hormones and prolactin in the diagnosis of breast cancer].
    Korolev VI; Skliar SIu; Chebotareva ED; Akimova RN
    Vopr Onkol; 1986; 32(11):55-9. PubMed ID: 3788082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumor markers in ovarian cancer].
    Lahousen M
    Jugosl Ginekol Perinatol; 1987; 27(3-4):73-5. PubMed ID: 3481005
    [No Abstract]   [Full Text] [Related]  

  • 15. [Serum levels of 4 tumor-associated antigens in the evaluation of the spread of breast carcinoma].
    Stefanović L; Kamenjicki E; Selir Z; Miljković L; Sterio B; Semnic R; Sljapić N
    Med Pregl; 1984; 37(3-4):107-12. PubMed ID: 6208469
    [No Abstract]   [Full Text] [Related]  

  • 16. [Immunohistochemical evaluation of several tumor markers (CEA, ferritin, Ca) and their correlation with estro-progestin receptor state in neoplasms].
    Forti E; Wolf D; Melia M
    Pathologica; 1985; 77(1049):241-9. PubMed ID: 3913892
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical study of the measurement of tissue polypeptide antigen in patients with breast cancer].
    Fukunaga M; Otsuka N; Yanagi M; Sone T; Muranaka A; Yanagimoto S; Tomomitsu T; Morita R; Ohama T; Sonoo H
    Gan No Rinsho; 1985 Jul; 31(8):923-8. PubMed ID: 4032770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biohumeral markers in the diagnosis of pancreatic carcinoma].
    Panucci A; Del Favero G; Falmis C; Brosolo P; Basso D; Pedrazzoli S; Baccaglini U; Marchioro L; Bonvilini P; Naccarato R
    Recenti Prog Med; 1985; 76(7-8):385-91. PubMed ID: 3865269
    [No Abstract]   [Full Text] [Related]  

  • 19. [Preliminary results of the clinical use of TPA (tissue polypeptide antigen)].
    Dalla Pria AF; Guolo P; Piaserico PL; Ricci G; Berlanda G; Gobbi V; Minello S
    Arch De Vecchi Anat Patol; 1983 Jul; 65(2-3):301-13. PubMed ID: 6680294
    [No Abstract]   [Full Text] [Related]  

  • 20. How can treatment response be measured in breast cancer patients?
    van Dalen A; van der Linde DL; Heering KJ; van Oudalblas AB
    Anticancer Res; 1993; 13(5C):1901-4. PubMed ID: 8267398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.